Enanta Pharma 15min Chart Sees KDJ Golden Cross and Bullish Marubozu.

Enanta's 15-minute chart has recently displayed a bullish signal, as indicated by the KDJ Golden Cross and Bullish Marubozu patterns on August 19th at 12:00. This suggests a shift in momentum towards the upside and potential for further price appreciation. The dominance of buyers in the market indicates a continuation of bullish momentum.

Enanta Pharmaceuticals (NASDAQ:ENTA) has shown signs of strong bullish momentum, as its 15-minute chart recently exhibited a KDJ Golden Cross and Bullish Marubozu pattern on August 19, 2025, at 12:00. This technical indicator suggests a potential increase in the stock price, with buyers gaining control of the market. The bullish momentum is likely to continue, indicating a positive outlook for the stock.

Analysts have been increasingly optimistic about Enanta's prospects. Citizens JMP analyst Roy Buchanan raised the price target on Enanta's stock to $25.00 from $24.00, maintaining a Market Outperform rating [1]. This move comes after Enanta reported fiscal third-quarter 2025 results that exceeded both analyst and consensus expectations, driven by strong revenues and continued expense reductions. The company ended the quarter with $204 million in cash and provided guidance that its cash position and continuing Mavyret income would fund operations into fiscal 2028 [1].

Enanta's next major clinical catalyst will be the Phase 2 results for zelicapavir, its oral N-protein inhibitor for RSV in high-risk adults, expected next month. Management is targeting approximately a one-day improvement in symptom resolution compared to placebo [1].

Additionally, Enanta Pharmaceuticals announced the U.S. Food and Drug Administration’s approval of MAVYRET as an eight-week treatment for acute hepatitis C, achieving a 96% cure rate in clinical trials [1]. This approval broadens the treatment’s indication to include both acute and chronic hepatitis C in adults and children three years and older.

Enanta reported fiscal Q3 2025 revenue of $18.3 million, up year-over-year, mainly from royalties on AbbVie’s hepatitis C drugs MAVYRET and MAVIRET [2]. The company's net loss narrowed to $18.26 million, with operating expenses ending at $37.21 million and an EPS of -$0.85. Enanta’s management says current cash and ongoing royalties should keep the business going through 2028. Wall Street agrees things are looking up: the consensus is ‘buy,’ with a median 12-month price target of $20 per share—almost 66% above the $6.90 closing price on August 8 [2].

Investors should pay close attention to Enanta's upcoming data releases and clinical trial results, as these could significantly impact the stock's performance. With four of six analysts rating the stock a ‘buy’ or ‘strong buy’ and a price target well above the recent share price, there’s renewed optimism for a stock rebound [2].

References:
[1] https://za.investing.com/news/analyst-ratings/citizens-jmp-raises-enanta-pharmaceuticals-stock-price-target-to-25-from-24-93CH-3833274
[2] https://finimize.com/content/enanta-pharmaceuticals-sees-narrower-losses-and-brighter-analyst-views